Lohit

Scientists reprogrammed leukemia to switch itself off, and it worked Researchers at the Institut Pasteur developed a new approach that changes how malignant B-cell leukemia shuts itself down, while also drawing the immune system into action. Most treatments try to remove cancer cells directly, but this method works by triggering a process that sends strong warning signals to immune cells, helping the body recognize and clear the disease. This response normally does not occur in B-cell leukemia because a key molecular component is missing. By combining three clinically used compounds, the researchers were able to work around this limitation and activate the immune response. Using advanced imaging in preclinical models, they observed immune cells rapidly moving in and clearing the leukemia. In these experiments, the disease did not just lessen, it was completely cleared. Although this approach has not yet been tested in patients, the findings point to a promising strategy that relies on immune-mediated tumor control, with the potential for faster clinical evaluation because existing compounds were used.